WallStreetZenWallStreetZen

NASDAQ: HALO
Halozyme Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Halozyme Therapeutics revenue was $1.08B for the trailing 12 months ending Mar 31, 2025, with 57.1% growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $264.9M, down 11.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, HALO annual revenue was $1.0B, with 22.4% growth year-over-year.

HALO past revenue growth

How has HALO's revenue growth performed historically?

Company
25.65%
Industry
1,361.15%
Market
34.96%
HALO's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
HALO's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
HALO's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

HALO revenue history

Current Revenue
$1.1B
Current Earnings
$485.4M
Current Profit Margin
44.8%

Be the first to know when HALO announces revenue.

HALO Revenue History By Year

HALO Yearly RevenueHALO RevenueHALO ChangeHALO Revenue Growth
2024-12-31$1.02B$186.07M+22.44%
2023-12-31$829.25M$169.14M+25.62%
2022-12-31$660.12M$216.81M+48.91%
2021-12-31$443.31M$175.72M+65.67%
2020-12-31$267.59M$71.60M+36.53%
2019-12-31$195.99M$44.13M+29.06%
2018-12-31$151.86M-$164.75M-52.04%
2017-12-31$316.61M$169.92M+115.84%
2016-12-31$146.69M$11.63M+8.61%
2015-12-31$135.06M$59.72M+79.28%
2014-12-31$75.33M$20.54M+37.47%
2013-12-31$54.80M$12.47M+29.47%
2012-12-31$42.33M-$13.76M-24.54%
2011-12-31$56.09M$42.46M+311.67%
2010-12-31$13.62M-$47.19k-0.35%
2009-12-31$13.67M$4.91M+55.99%
2008-12-31$8.76M$4.96M+130.66%
2007-12-31$3.80M$2.82M+287.02%
2006-12-31$981.75k$854.54k+671.76%
2005-12-31$127.21kN/AN/A
2004-12-31$0.00N/AN/A
2003-12-31$0.00-$87.77k-100.00%
2002-12-31$87.77kN/AN/A
2001-12-31N/AN/AN/A

1 of 2

Halozyme Therapeutics Revenue FAQ

What was HALO's revenue last quarter?

On Invalid Date, Halozyme Therapeutics (NASDAQ: HALO) reported Q1 2025 revenue of $264.86 million up 35.22% year over year. In the same quarter last year, Halozyme Therapeutics's revenue was $195.88 million.

What was Halozyme Therapeutics's revenue in 2024?

Halozyme Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $1.02 billion, a 22.44% increase year over year.

How much does Halozyme Therapeutics make in a day?

Based on Halozyme Therapeutics annual revenue for the past five years, HALO makes an average of $1,761,970.96 per day.

What was Halozyme Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Halozyme Therapeutics's revenue has grown 25.65% year over year. This is 1,335.5 percentage points lower than the US Biotechnology industry revenue growth rate of 1,361.15%. Halozyme Therapeutics's revenue in the past year totaled $1.08 billion.

How much does Halozyme Therapeutics make in a year?

Halozyme Therapeutics's revenue by year for the past five years is:
  • Halozyme Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $1.02 billion, a 22.44% increase year over year.
  • Halozyme Therapeutics's annual revenue for Dec 31, 2023 was $829.25 million, a 25.62% increase from 2022.
  • Halozyme Therapeutics's annual revenue for 2022 was $660.12 million, a 48.91% increase from 2021.
  • Halozyme Therapeutics's annual revenue for 2021 was $443.31 million, a 65.67% increase from 2020.
  • Halozyme Therapeutics's annual revenue for 2020 was $267.59 million, a 36.53% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.